Methods of preparing gaseous precursor-filled microspheres

a precursor and gaseous technology, applied in the field of gaseous precursor-filled liposome preparation methods and apparatus, can solve the problems of inability to carry out portable examination, inability to perform mri, and unknown dangers of x-rays, and achieve the effect of cost saving

Inactive Publication Date: 2005-07-28
LANTHEUS MEDICAL IMAGING INC
View PDF3 Cites 36 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024] The present invention provides methods and apparatus for preparing temperature activated gaseous precursor-filled liposomes suitable for use as contrast agents for ultrasonic imaging or as drug delivery agents. The methods of the present invention provide the advantages, for example, of simplicity and potential cost savings during manufacturing of temperature activated gaseous precursor-filled liposomes.
[0026] Unexpectedly, the temperature activated gaseous precursor-filled liposomes prepared in accordance with the methods of the present invention possess a number of surprising yet highly beneficial characteristics. For example, gaseous precursor-filled liposomes are advantageous due to their biocompatibility and the ease with which lipophilic compounds can be made to cross cell membranes after the liposomes are ruptured. The liposomes of the invention also exhibit intense echogenicity on ultrasound, are highly stable to pressure, and / or generally possess a long storage life, either when stored dry or suspended in a liquid medium. The echogenicity of the liposomes is of importance to the diagnostic and therapeutic applications of the liposomes made according to the invention. The gaseous precursor-filled liposomes also have the advantages, for example, of stable particle size, low toxicity and compliant membranes. It is believed that the flexible membranes of the gaseous precursor-filled liposomes may be useful in aiding the accumulation or targeting of these liposomes to tissues such as tumors.
[0027] The temperature activated gaseous precursor-filled liposomes made according to the present invention thus have superior characteristics for ultrasound contrast imaging. When inside an aqueous or tissue media, the gaseous precursor-filled liposome creates an interface for the enhanced absorption of sound. The gaseous precursor-filled liposomes are therefore useful in imaging a patient generally, and / or in diagnosing the presence of diseased tissue in a patient as well as in tissue heating and the facilitation of drug release or activation.

Problems solved by technology

X-rays, however, are known to be somewhat dangerous, since the radiation employed in X-rays is ionizing, and the various deleterious effects of ionizing radiation are cumulative.
This technique, however, has various drawbacks such as expense and the fact that it cannot be conducted as a portable examination.
In addition, MRI is not available at many medical centers.
Nuclear medicine techniques, however, suffer from poor spatial resolution and expose the animal or patient to the deleterious effects of radiation.
Furthermore, the handling and disposal of radionuclides is problematic.
However, despite these various technological improvements, ultrasound is still an imperfect tool in a number of respects, particularly with regard to the imaging and detection of disease in the liver and spleen, kidneys, heart and vasculature, including measuring blood flow.
The methods and materials in the prior art for introduction of genetic materials, for example, to living cells is limited and ineffective.
These methods have all been relatively ineffective in vivo and only of limited use for cell culture transfection.
None of these methods potentiate local release, delivery and integration of genetic material to the target cell.
Great strides have been made in characterizing genetic diseases and in understanding protein transcription but relatively little progress has been made in delivering genetic material to cells for treatment of human and animal disease.
A principal difficulty has been to deliver the genetic material from the extracellular space to the intracellular space or even to effectively localize genetic material at the surface of selected cell membranes.
Whole virus has been used but the amount of genetic material that can be placed inside of the viral capsule is limited and there is concern about possible dangerous interactions that might be caused by live virus.
Despite extensive work on viral vectors, it has been difficult to develop a successfully targeted viral mediated vector for delivery of genetic material in vivo.
Conventional, liquid-containing liposomes have been used to deliver genetic material to cells in cell culture but have mainly been ineffective in vivo for cellular delivery of genetic material.
For example, cationic liposome transfection techniques have not worked effectively in vivo.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of preparing gaseous precursor-filled microspheres
  • Methods of preparing gaseous precursor-filled microspheres
  • Methods of preparing gaseous precursor-filled microspheres

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Gas-Filled Lipid Spheres from Perfluorobutane

[0219] Gaseous precursor-containing liposomes were prepared using perfluorobutane (Pfaltz and Bauer, Waterbury, Conn.) as follows: A 5 mL solution of lipid, 5 mg per ml, lipid=87 mole percent DPPC, 8 mole percent DPPE-PEG 5,000, 5 mole percent dipalmitoylphosphatidic acid (all lipids from Avanti Polar Lipids, Alabaster, Ala.), in 8:1:1 normal saline:glycerol:propylene glycol, was placed in a glass bottle with a rubber stopper (volume of bottle=15.8 ml). Air was evacuated from the bottle using a vacuum pump, Model Welch 2-Stage DirecTorr Pump (VWR Scientific, Cerritos, Calif.) by connecting the hose to the bottle through a 18 gauge needle which perforated the rubber stopper. After removing the gas via vacuum, perfluorobutane was placed in the stoppered bottle via another 18 gauge needle connected to tubing attached to the canister of perfluorobutane. This process was repeated 5 time such that any traces of air were removed ...

example 2

Preparation of Gaseous Precursors Via Microfluidization

[0223] Gaseous precursor-filled lipid bilayers were prepared as in Example 1 except, after addition of the gaseous precursor, the contents were microfluidized through six passes on a Microfluidics microfluidizer (Microfluidics Inc., Newton, Mass.). The stroke pressure ranged between 10,000 and 20,000 psi. Continuing with the preparation as per Example 1, produced gas-filled lipid bilayers with gaseous precursor encapsulated.

example 3

Formulation of Gas-Filled Lipid Bilayers using Phosphatidic Acid and Dipalmitoyphosphatidylcholine

[0224] Gas-filled lipid bilayers were prepared as set forth in Example 6 except for the fact that DPPC was used in combination with 5 mole % phosphatidic acid (Avanti Polar Lipids, Alabaster, Ala.). Formulation of gas-filled lipid bilayers resulted in an increase in solubility as exemplified by a decrease in the amount of lipid particulate in the lower aqueous vehicle layer. Resultant sizing appeared to decrease the overall mean size vs. DPPC alone to less than 40 μm.

EXAMPLE 4

Formulation of Gas-Filled Lipid Bilayers using Phosphatidic Acid, Dipalmitoylphosphatidylethanolamine-PEG 5,000 and Dipalmitoylphosphatidylcholine

[0225] Perfluorobutane encapsulated lipid bilayers were formed as discussed in Example 3 except that the lipid formulation contained 82% dipalmitoylphosphatidylcholine, 10 mole % dipalmitoylphosphatidic acid, and 8 mole % dipalmitoylphosphatidylethanolamine-PEG 5,000 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of and apparatus for preparing gas-filled microspheres are described. Gas-filled microspheres prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.

Description

RELATED APPLICATIONS [0001] This application is a divisional of copending U.S. Ser. No. 09 / 118,329, filed Jul. 17, 1998, now allowed, which in turn is a divisional of U.S. Ser. No. 08 / 487,230, filed Jun. 6, 1995, now U.S. Pat. No. 5,853,752, which is a divisional of U.S. Ser. No. 08 / 159,687, filed Nov. 30, 1993, now U.S. Pat. No. 5,585,112, which is a continuation-in-part of U.S. Ser. No. 08 / 160,232 filed Nov. 30, 1993, now U.S. Pat. No. 5,542,935, and a continuation-in-part of U.S. Ser. No. 08 / 159,674, filed Nov. 30, 1993, now abandoned. Said 08 / 160,232 and 08 / 159,674 are continuations-in-part of U.S. Ser. No. 08 / 076,239 filed Jun. 11, 1993, now U.S. Pat. No. 5,469,854, which is a continuation-in-part of U.S. Ser. No. 07 / 717,084, now U.S. Pat. No. 5,228,446, and U.S. Ser. No. 07 / 716,899, now abandoned, both of which were filed Jun. 18, 1991. Said 07 / 717,084 and 07 / 716,899 are continuations-in-part of U.S. Ser. No. 07 / 569,828, filed Aug. 20, 1990, now U.S. Pat. No. 5,088,499, which ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/127A61K41/00A61K47/48A61K49/18A61K49/22A61M5/31
CPCA61K9/127A61K9/1277A61K9/1278A61K41/0028A61M5/3145A61K47/48869A61K49/223A61K49/227A61K41/0052A61K47/6925A61P43/00
Inventor UNGER, EVAN C.FRITZ, THOMAS A.MATSUNAGA, TERRYRAMASWAMI, VARADARAJANYELLOWHAIR, DAVIDWU, GUANLI
Owner LANTHEUS MEDICAL IMAGING INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products